IVERIC bio, Inc. (ISEE) Income Statement Analysis

See more : Lamtex Holdings Limited (1041.HK) Income Statement Analysis – Financial Results

Complete financial analysis of IVERIC bio, Inc. (ISEE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IVERIC bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

IVERIC bio, Inc. (ISEE)

Industry: Biotechnology

Sector: Healthcare

Website: https://ivericbio.com

About IVERIC bio, Inc.

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	0.00	0.00	0.00	0.00	0.00	209.98M	50.91M	51.51M	41.26M	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	209.98M	50.91M	51.51M	41.26M	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%
Research & Development	117.01M	85.07M	62.78M	39.64M	41.74M	66.29M	196.30M	131.01M	88.39M	33.22M	6.79M	13.90M
General & Administrative	72.89M	29.69M	25.95M	21.63M	23.61M	35.68M	50.18M	44.02M	33.39M	14.21M	6.89M	5.74M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	72.89M	29.69M	25.95M	21.63M	23.61M	35.68M	50.18M	44.02M	33.39M	14.21M	6.89M	5.74M
Other Expenses	62.00K	-10.00K	-6.00K	151.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	189.91M	114.76M	88.74M	61.27M	65.35M	101.97M	246.47M	175.03M	121.77M	47.43M	13.68M	19.63M
Cost & Expenses	189.91M	114.76M	88.74M	61.27M	65.35M	101.97M	246.47M	175.03M	121.77M	47.43M	13.68M	19.63M
Interest Income	2.26M	245.00K	500.00K	2.15M	2.39M	1.52M	1.70M	971.00K	217.00K	-1.45M	368.00	2.00K
Interest Expense	2.26M	0.00	500.00K	2.15M	2.39M	1.52M	1.70M	971.00K	217.00K	1.45M	507.52K	0.00
Depreciation & Amortization	-2.37M	39.00K	143.00K	162.00K	183.00K	2.76M	757.00K	698.00K	127.00K	20.00K	31.16K	32.00K
EBITDA	-192.28M	-114.76M	-88.74M	-61.27M	62.21M	112.26M	-193.07M	-121.81M	-80.17M	-49.67M	-14.02M	-19.63M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	53.46%	-379.24%	-236.49%	-194.31%	0.00%	0.00%	0.00%
Operating Income	-189.91M	-114.76M	-88.74M	-61.27M	-65.35M	108.01M	-195.56M	-123.53M	-80.51M	-47.43M	-13.68M	-19.63M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	51.44%	-384.14%	-239.84%	-195.14%	0.00%	0.00%	0.00%
Total Other Income/Expenses	4.70M	235.00K	494.00K	2.30M	127.37M	1.49M	1.74M	1.02M	217.00K	-3.72M	-881.03K	-28.00K
Income Before Tax	-185.21M	-114.52M	-88.24M	-58.97M	62.02M	109.49M	-193.83M	-122.50M	-80.30M	-51.15M	-14.56M	-19.66M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	52.15%	-380.73%	-237.85%	-194.61%	0.00%	0.00%	0.00%
Income Tax Expense	-9.47M	-284.00K	-3.70M	-111.00K	-1.06M	-4.71M	-406.00K	-16.79M	17.89M	-2.27M	-373.50K	-1.03M
Net Income	-175.75M	-114.24M	-84.55M	-58.86M	63.09M	114.21M	-193.42M	-105.72M	-98.19M	-51.15M	-14.56M	-18.63M
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	54.39%	-379.93%	-205.26%	-237.98%	0.00%	0.00%	0.00%
EPS	-1.45	-1.12	-1.14	-1.39	1.70	3.18	-5.45	-3.06	-2.95	-5.68	-0.65	-0.83
EPS Diluted	-1.45	-1.12	-1.14	-1.39	1.70	3.17	-5.45	-3.06	-2.95	-5.68	-0.65	-0.83
Weighted Avg Shares Out	121.04M	101.87M	74.19M	42.22M	37.09M	35.92M	35.49M	34.58M	33.26M	9.00M	22.49M	22.51M
Weighted Avg Shares Out (Dil)	121.04M	101.87M	74.19M	42.22M	37.09M	36.01M	35.49M	34.58M	33.26M	9.00M	22.49M	22.51M

Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

September 20, 2023prnewswire.com

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States 1,2 Eric and his mother, Jamey, are sharing their family's story of GA and AMD to raise...

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

September 18, 2023prnewswire.com

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month results , with no new safety signals identified TOKYO, Sept....

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

August 17, 2023prnewswire.com

TOKYO , Aug. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational...

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

August 4, 2023prnewswire.com

IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed loss of photoreceptors and disease progression as early as...

Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc

July 28, 2023gurufocus.com

Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an...

Astellas Completes Acquisition of Iveric Bio

July 11, 2023prnewswire.com

TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio,...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR

May 1, 2023headlinesoftoday.com

NEW YORK, May 1, 2023 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Iveric bio, Inc....